Getinge B stock trades near yearly highs after solid first-half results

Getinge AB B stock (ISIN SE0000202624) recently changed hands around SEK 238.70 on Nasdaq Stockholm as of September 18, 2026, keeping the shares near their yearly highs on the back of solid reported figures and a steady year-to-date gain.

First-half performance supports valuation

Getinge AB, a Swedish healthcare equipment and services group, reported higher sales and earnings in its most recent half-year results for fiscal 2026, giving investors more confidence in the underlying business. The interim report for the first half of 2026 showed that revenue increased compared with the same period of 2025, while operating profitability improved, reflecting a combination of steady demand in hospital equipment and cost-control efforts.

In that half-year report for 2026, management highlighted that the company’s margins widened versus the prior year as pricing actions and a more favorable product mix offset cost pressures. Investors often focus on the development of the operating margin because it determines how much of the revenue growth ultimately reaches the bottom line. Historical figures from earlier fiscal years had already pointed to a gradual improvement, and the latest half-year numbers confirm that this trend has continued into 2026.

Stock trades close to 52-week high

Per a recent price overview on September 18, 2026, Getinge B last closed at SEK 238.70 on Nasdaq Stockholm, with the shares up 1.79% over the previous five trading days and 9.05% since January 1, 2026. The current price is near the upper end of the 52-week trading range, indicating that the stock has already priced in a significant part of the improvement in fundamentals, but still leaves room for additional upside if earnings continue to grow.

The same overview shows that Getinge B’s 52-week low is materially below the current level, while its 52-week high lies not far above SEK 238.70, underlining how much the shares have recovered over the past months. The fact that the stock is now trading close to its high of the year suggests that the market is rewarding the company for its more resilient earnings profile and the clearer visibility on hospital and life-science capital spending cycles.

Analyst view and risk factors

Analyst commentary around Getinge B in recent months has largely focused on the company’s ability to sustain margin gains in a more normal demand environment after the pandemic period. While the latest half-year report for 2026 showed a year-on-year increase in revenue and a better operating result, some observers remain cautious about the potential impact of pricing pressure from hospital systems and the need for ongoing investment in innovation and compliance.

For investors, one key risk is that capital spending in healthcare could slow if budget constraints return, which would affect demand for big-ticket equipment. Another factor is currency movements, as a significant share of Getinge’s sales are generated outside Sweden and translated back into SEK for reporting. These elements can influence both revenue growth and margins, and therefore the sustainability of the current valuation level.

Getinge B stock price snapshot

As of September 18, 2026, Getinge B stock closed at SEK 238.70 on Nasdaq Stockholm, representing a gain of 9.05% since the start of 2026 and keeping the shares close to their 52-week high within the established trading range. This price level and performance profile reflect a combination of improved first-half earnings, margin progress and investor confidence in the company’s position in the healthcare equipment market.

More news and analyses on Getinge B stock